^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:sunvozertinib (DZD9008) (EGFR inhibitor, HER2 inhibitor, BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

    Excerpt:
    ...To evaluate anti-tumor activity of DZD9008 in advanced NSCLC patients with EGFR Exon20 insertion, HER2 Exon20 insertion or EGFR uncommon mutations at defined dose(s) (Part B)`Part B: Objective Response Rate (ORR) according to RECIST 1.1....
    Trial ID:
    WK-KONG1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Published date:
    07/06/2022
    Excerpt:
    In addition, the preliminary antitumor activity of sunvo­zertinib was also observed in patients with EGFR sensitizing mutation, EGFR sensitizing/T790M double mutation, and HER2exon20ins (Supplementary Table S8).
    DOI:
    https://doi.org/10.1158/2159-8290.CD-21-1615